The BHLHE40 Knockout SK-HEP-1 Polyclonal Cells provided by Ascent Research are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human hepatic adenocarcinoma cell line SK-HEP-1, featuring targeted disruption of the BHLHE40 gene. This polyclonal product delivers a heterogeneous loss-of-function model ideal for investigating BHLHE40-dependent transcriptional repression without the selection of a single clonal isolate, thereby retaining the diverse genetic background inherent to the edited pool and recapitulating population-level responses observed in tumor biology.
The SK-HEP-1 host cell line was originally established from the ascitic fluid of a patient with liver adenocarcinoma and exhibits notable endothelial-like characteristics, including the expression of endothelial markers and the ability to form vascular structures. These features make SK-HEP-1 a widely accepted model for studying liver sinusoidal endothelium, angiogenesis, and vascular mimicry in hepatocellular carcinoma. Its dual epithelial-endothelial phenotype offers a unique platform for examining the interplay between tumor cells and the microenvironment, particularly in the context of hypoxia-driven processes and metastatic progression.
BHLHE40 encodes a basic helix-loop-helix transcriptional repressor that integrates signals from multiple upstream regulators, including HIF1A, TGFB1, the CLOCK/BMAL1 circadian complex, and TP53. BHLHE40 interacts with co-repressors such as HDAC1 and HDAC2 and with clock components ARNTL/BMAL1 and CLOCK to repress transcription of downstream targets, among which CCND1, MMP1, VEGFA, CXCR4, and PER1 are critical mediators of cell cycle progression, invasion, angiogenesis, and circadian rhythms. A representative mechanistic axis involves HIF1A-mediated activation of BHLHE40, which in turn represses VEGFA and MMP1, thereby modulating hypoxia-induced angiogenic and invasive responses.
In the SK-HEP-1 background, disruption of BHLHE40 abrogates this transcriptional repression, permitting direct interrogation of how BHLHE40 loss alters hypoxia signaling, circadian gene expression, and tumorigenic phenotypes. This model is especially pertinent for studies linking circadian disruption to hepatocellular carcinoma pathogenesis, as BHLHE40 serves as a nexus between the molecular clock and cancer hallmarks. The polyclonal nature of the knockout pool also facilitates the examination of heterogeneous responses to therapeutic agents, mimicking the complexity of clinical tumors.
Research applications are diverse and include the study of hypoxia-mediated gene regulation through ChIP-qPCR analysis of E-box occupancy or transcriptome profiling by RNA-seq, investigation of circadian clock dysfunction via RT-qPCR for PER1 and CRY1, and screening for BHLHE40-dependent drug sensitivity using sorafenib in proliferation and migration assays. The model further supports angiogenesis and metastasis research by enabling Transwell invasion and hypoxia exposure assays with quantification of VEGFA and MMP1. For further information, please contact Ascent Research.
